Vivozon Pharmaceutical announced on the 4th that its non-narcotic analgesic innovative new drug 'UNAFRA Inj.' won the Grand Award in the new drug development category at the 26th Korea New Drug Development Awards.
The Korea New Drug Development Award is the first domestic award for new drug development, established in 1999 to promote the development of the domestic biohealth industry and to inspire research and development in new drugs, commemorating the achievements of high-value new drug development companies and those creating new technologies and exporting technologies.
The Korea Drug Research Association organizes the event, supported by the Ministry of Science and ICT, the Ministry of Health and Welfare, and the Ministry of Trade, Industry and Energy.
Vivozon Pharmaceutical's UNAFRA Inj. is a non-narcotic analgesic injection used for moderate to severe acute pain control after surgery. The company secured statistical significance in domestic clinical phase 3 trials targeting patients after laparoscopic colectomy and obtained product approval for UNAFRA Inj. as the 38th domestically produced new drug from the Ministry of Food and Drug Safety in December of last year.
Jang Boo-hwan, CEO of Vivozon Pharmaceutical, said, "The award in the new drug development category demonstrated the excellent efficacy and value of the innovative new drug UNAFRA Inj., and it was possible thanks to the dedication of all employees who have been devoted to continuous challenges and passion for innovative new drug development."